- Home
- Publications
- Publication Search
- Publication Details
Title
Complement System: a Neglected Pathway in Immunotherapy
Authors
Keywords
-
Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-29
DOI
10.1007/s12016-019-08741-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
- (2019) Cristina Bagacean et al. Journal for ImmunoTherapy of Cancer
- Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
- (2019) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Toll-Like Receptors, Infections, and Rheumatoid Arthritis
- (2019) Marina I. Arleevskaya et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives
- (2019) Cristina Bagacean et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms
- (2019) Marina I. Arleevskaya et al. Frontiers in Microbiology
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
- (2018) M S Czuczman et al. ANNALS OF ONCOLOGY
- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
- (2018) Maren Knödler et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II-III HER-2/ neu positive breast cancer: a retrospective, single institution experience
- (2018) Rashmi K. Murthy et al. Clinical Breast Cancer
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
- (2018) Chezi Ganzel et al. HAEMATOLOGICA
- Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia
- (2018) Nathaniel J Buteyn et al. INTERNATIONAL IMMUNOLOGY
- Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
- (2018) Leonhard Busch et al. LEUKEMIA
- Clinical features of patients with homozygous complement C4A or C4B deficiency
- (2018) Inka Liesmaa et al. PLoS One
- Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor
- (2018) Taroh Kinoshita SEMINARS IN HEMATOLOGY
- Mogamulizumab Tops Standard of Care for CTCL
- (2018) Cancer Discovery
- Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
- (2018) Chezi Ganzel et al. HAEMATOLOGICA
- Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
- (2018) Carlos Cuesta-Mateos et al. Frontiers in Immunology
- Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation
- (2018) Yoshitaka Inoue et al. BONE MARROW TRANSPLANTATION
- Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
- (2018) Meletios A. Dimopoulos et al. CANCER
- Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies
- (2018) Antony P. Martin et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma
- (2018) Sarah Chehab et al. Future Oncology
- Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
- (2018) Giandomenico Roviello et al. LANCET ONCOLOGY
- Daratumumab in Primary Effusion Lymphoma
- (2018) Nirav N. Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer
- (2018) Raffaele Addeo et al. ONCOLOGY
- Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
- (2018) Anne Bordron et al. Oncotarget
- Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
- (2018) Jong Wook Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice
- (2018) Alexandra Francian et al. Nanomedicine-Nanotechnology Biology and Medicine
- Immunotherapy in myasthenia gravis in the era of biologics
- (2018) Marinos C. Dalakas Nature Reviews Neurology
- Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature
- (2018) Nina Kello et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages
- (2018) Haoran Zha et al. Cancer Immunology Research
- Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab
- (2018) Andrew Iskandar et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
- (2017) Guoqing Wei et al. Journal of Hematology & Oncology
- Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
- (2017) Manoj K. Kashyap et al. Journal of Hematology & Oncology
- Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells
- (2017) Annalina Tammen et al. JOURNAL OF IMMUNOLOGY
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
- (2017) David R.W. Jayne et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Systemic lupus erythematosus with C1q deficiency: treatment with fresh frozen plasma
- (2017) Z Ekinci et al. LUPUS
- Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection
- (2017) Julien Henry et al. RHEUMATOLOGY
- Targeting CD157 in AML using a novel, Fc-engineered antibody construct
- (2017) Christina Krupka et al. Oncotarget
- High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine
- (2017) Lucy A. McNamara et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
- (2017) Stina Wichert et al. PLoS One
- Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
- (2017) Yanyan Zhang et al. Scientific Reports
- Catastrophic antiphospholipid syndrome: The current management approach
- (2016) Ignasi Rodriguez-Pintó et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
- (2016) Carmen Martínez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia
- (2016) Tadeusz Robak et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia
- (2016) Jeevisha Bajaj et al. CANCER CELL
- Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity
- (2016) Clive S. Zent et al. FEBS Journal
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises
- (2016) Cristina Bagacean et al. Immunotherapy
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
- (2016) Pirow Bekker et al. PLoS One
- Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies
- (2016) Capucine L. Grandjean et al. Scientific Reports
- Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors
- (2015) Günter Krause et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages
- (2015) A. K. Church et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
- (2015) M. Hansson et al. CLINICAL CANCER RESEARCH
- Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion
- (2015) Adrian Tempescul et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
- (2015) L. Rasche et al. HAEMATOLOGICA
- Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue
- (2015) T.A.M. Bouwens et al. JOURNAL OF NEUROIMMUNOLOGY
- Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndrome
- (2015) Noémie Abisror et al. PRESSE MEDICALE
- Abatacept efficacy in rheumatoid arthritis is dependent upon baseline blood B-cell levels
- (2015) Pierre Gazeau et al. RHEUMATOLOGY
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
- (2015) L. Rasche et al. HAEMATOLOGICA
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
- (2014) J. A. Woyach et al. BLOOD
- Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™therapeutic protein, for relapsed or refractory NHL patients
- (2014) John M. Pagel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Complement in Antibody-Based Tumor Therapy
- (2014) Stefanie Derer et al. CRITICAL REVIEWS IN IMMUNOLOGY
- Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
- (2014) Nuray Gül et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
- (2014) Sven de Vos et al. Journal of Hematology & Oncology
- Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
- (2014) O Middleton et al. LEUKEMIA
- Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
- (2014) P Macor et al. LEUKEMIA
- A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
- (2014) Simon Z. He et al. LEUKEMIA & LYMPHOMA
- Complement Nomenclature 2014
- (2014) Claudia Kemper et al. MOLECULAR IMMUNOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- C1q as a unique player in angiogenesis with therapeutic implication in wound healing
- (2014) F. Bossi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
- (2013) Peter Hillmen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting the complement system in systemic lupus erythematosus and other diseases
- (2013) Maria-Louise Barilla-LaBarca et al. CLINICAL IMMUNOLOGY
- Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
- (2013) Gillian M. Keating DRUGS
- Complement and autoimmunity
- (2013) Eleonora Ballanti et al. IMMUNOLOGIC RESEARCH
- The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
- (2013) Fabricio Montalvao et al. JOURNAL OF CLINICAL INVESTIGATION
- C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN
- (2013) H. Xiao et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
- (2013) Karen Silence et al. mAbs
- Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
- (2013) Edwin K.S. Wong et al. MOLECULAR IMMUNOLOGY
- Complement factor H related proteins (CFHRs)
- (2013) Christine Skerka et al. MOLECULAR IMMUNOLOGY
- Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5
- (2013) Paolo Durigutto et al. PLoS One
- Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
- (2012) Bridget Charbonneau et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
- (2012) M. S. Czuczman et al. ANNALS OF ONCOLOGY
- Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5
- (2012) Paolo Macor et al. ARTHRITIS AND RHEUMATISM
- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
- (2012) M. S. Czuczman et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
- (2012) William Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Analysis of Binding Sites on Complement Factor I Using ArtificialN-Linked Glycosylation
- (2012) Jose I. Sanchez-Gallego et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
- (2012) John C. Byrd et al. LEUKEMIA & LYMPHOMA
- The Lectin Pathway of Complement Activation Is a Critical Component of the Innate Immune Response to Pneumococcal Infection
- (2012) Youssif M. Ali et al. PLoS Pathogens
- Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy
- (2011) Divi Cornec et al. ANNALS OF HEMATOLOGY
- Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
- (2011) S. Veeramani et al. BLOOD
- A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
- (2011) Elizabeth Ward et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ofatumumab in the treatment of low-grade non-Hodgkin’s lymphomas and chronic lymphocytic leukemia
- (2011) Celeste Bello et al. Expert Review of Clinical Immunology
- Molecular basis of hereditary C1q deficiency—revisited: identification of several novel disease-causing mutations
- (2011) L Schejbel et al. GENES AND IMMUNITY
- The new face of anaphylatoxins in immune regulation
- (2011) Wuding Zhou IMMUNOBIOLOGY
- Plasma Exchange and Rituximab in the Management of Acute Occlusive Retinal Vasculopathy Secondary to Systemic Lupus Erythematosus.
- (2011) Erika Damato et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγnull mouse lymphoma model
- (2010) Fumihiko Sato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- (2010) Kensei Tobinai et al. CANCER SCIENCE
- Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis
- (2010) Rubens Costa et al. CLINICAL RHEUMATOLOGY
- Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
- (2010) F. Navid et al. CURRENT CANCER DRUG TARGETS
- IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients
- (2010) D.T. Nguyen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia
- (2010) Tadeusz Robak et al. Expert Review of Anticancer Therapy
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
- (2010) Wei Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma
- (2009) Abraham Klepfish et al. Annals of the New York Academy of Sciences
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation
- (2009) S. Heinen et al. BLOOD
- A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
- (2009) Pina M. Cardarelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The complement system in systemic autoimmune disease
- (2009) Min Chen et al. JOURNAL OF AUTOIMMUNITY
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic potential of complement modulation
- (2009) Eric Wagner et al. NATURE REVIEWS DRUG DISCOVERY
- The human IgM pentamer is a mushroom-shaped molecule with a flexural bias
- (2009) D. M. Czajkowsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
- (2008) A. Hagenbeek et al. BLOOD
- Modulation of Protective T Cell Immunity by Complement Inhibitor Expression on Tumor Cells
- (2008) J. C. Varela et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
- (2008) E. Racila et al. CLINICAL CANCER RESEARCH
- Terminal sugars of Fc glycans influence antibody effector functions of IgGs
- (2008) T Shantha Raju CURRENT OPINION IN IMMUNOLOGY
- Functional roles for C5a receptors in sepsis
- (2008) Daniel Rittirsch et al. NATURE MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started